T1	SectionAnnotate 216 220	HPI:
T2	SectionAnnotate 3490 3511	Past Medical History:
T3	SectionAnnotate 3695 3709	Family History
T4	SectionAnnotate 3918 3932	Social History
T5	SectionAnnotate 4391 4415	Social History Narrative
T6	SectionSkip 4552 5718	Outpatient Encounter Prescriptions as of 04/13/2017   Medication Sig Dispense Refill    buPROPion (WELLBUTRIN SR) 150 mg 12 hr tablet Take 150 mg by mouth 2 (two) times daily.      cetirizine (ZYRTEC) 10 mg tablet Take 1 tablet (10 mg total) by mouth Daily. 30 tablet 6    docusate sodium (COLACE) 250 mg capsule Take 1 capsule (250 mg total) by mouth 2 (two) times daily as needed for Constipation. 60 capsule 1    hydrOXYzine (ATARAX) 10 mg tablet Take 10 mg by mouth 3 (three) times daily as needed for Itching.      ibuprofen (ADVIL,MOTRIN) 600 mg tablet Take 1 tablet (600 mg total) by mouth every 6 (six) hours as needed for Pain. 60 tablet 1    iron 18 mg TAB tablet Take by mouth.      labetalol (NORMODYNE) 100 mg tablet Take 100 mg by mouth 2 (two) times daily.      PNV NO.122/IRON/FOLIC ACID (PRENATAL MULTI ORAL) Take by mouth.      triamcinolone (KENALOG) 0.1 % cream Apply topically 2 (two) times daily. Use as instructed      UNABLE TO FIND Med Name: Fluoxetine      zolpidem (AMBIEN) 5 mg tablet Take 5 mg by mouth nightly as needed for Sleep.       No facility-administered encounter medications on file as of 04/13/2017.        No Known
T7	SectionAnnotate 5735 5753	Review of Systems:
T12	SectionSkip 12891 14237	Findings:  This bilateral breast MRI exam demonstrates marked background enhancement.  The breasts are composed of heterogeneous fibroglandular tissue and fat.    RIGHT Breast:  Marked background enhancement is seen, with the most confluent area of enhancement occurring in the right upper outer breast, posterior depth (best seen on post-gadolinium axial image #101, sagittal image #363), measuring up to 3.5 cm in AP dimension. This is only slightly more prominent on the right compared with the left side, and appears to correspond with the area noted on recent PET CT.  A more superficial and smaller right axillary tail mass is seen measuring approximately 1.5 x 0.5 x 1.0 cm (best seen on post-gadolinium axial image #104, sagittal image #369), which 
 demonstrates suggestion of susceptibility artifact on T1 imaging and may correspond to the area of calcifications seen on mammogram. This appears to enhance with slightly greater intensity than the breast tissue described above.    LEFT Breast:  Marked background enhancement is seen. No abnormal areas of enhancement or other MRI features of malignancy are identified.    OTHER:  Markedly enlarged right axillary lymph nodes are seen with cortical thickness measuring up to 1 cm. Left axillary lymph nodes are unremarkable. Visualized abdomen and remainder of the chest is unremarkable.
T13	SectionSkip 15199 16370	FINDINGS:    Brain: Study limited by patient motion. Unremarkable, symmetric, FDG uptake is seen throughout the cortical gray matter, basal ganglia and the cerebellum. No mass effect. While these images appear within normal limits, MRI is recommended to rule out intracranial and/or skull base metastases if clinically indicated.    Neck: Multiple hypermetabolic right cervical lymph nodes measuring up to 
 2.2 x 1.8 cm in the jugular chain with SUV max of 6.0 (series 3 image 50). Additional 0.8 cm left Vb lymph node with SUV max of 2.4. Scattered non-FDG avid subcentimeter thyroid nodules.     Chest: Multiple hypermetabolic right axillary lymph nodes measuring up to 2.7 x 1.7 cm with SUV max of 4.5 (series 3 image 67). Previously biopsied 0.9 cm hypermetabolic right supraclavicular lymph node with SUV max of 3.5. Heterogeneous breast tissue noted bilaterally with heterogeneous FDG avidity, with an area of increased FDG avidity which appears slightly nodular in the upper outer right breast. Lungs are clear.     Abdomen/Pelvis: Unremarkable abdomino-pelvic organs. Normal appendix. No hypermetabolic lymphadenopathy.    Musculoskeletal: No metastatic disease.
T14	SectionAnnotate 16947 16978	Assessment and Recommendations:
T15	PROBLEM 78 82	a HR
T16	PROBLEM 84 108	metastatic breast cancer
T17	PROBLEM 119 130	lymph nodes
T18	TREATMENT 172 189	treatment options
T19	PROBLEM 297 326	a new right lateral neck lump
T20	TEST 329 337	Her exam
T21	PROBLEM 354 373	a hard, mobile mass
T22	PROBLEM 511 526	the lymph nodes
T23	PROBLEM 552 594	0.5 cm mobile mass in right anterior chain
T24	PROBLEM 596 656	2 x 1 cm mass and subcentimeter masses of right lateral neck
T25	TEST 687 692	a CBC
T26	TEST 763 770	imaging
T27	PROBLEM 849 853	sore
T28	TEST 859 868	palpation
T29	TEST 871 879	Her exam
T30	PROBLEM 1101 1110	the nodes
T31	PROBLEM 1168 1172	pain
T32	TEST 1175 1183	Her exam
T33	PROBLEM 1210 1218	fullness
T34	PROBLEM 1297 1314	a firm round mass
T35	TEST 1408 1415	Neck US
T36	PROBLEM 1417 1493	diffuse bilateral submandibular, anterior, and posterior cervical adenopathy
T37	TEST 1525 1550	R anterior cervical chain
T38	TEST 1565 1584	L anterior cervical
T39	TEST 1599 1634	L posterior lateral neck inferiorly
T40	TEST 1650 1657	thyroid
T41	TEST 1683 1685	US
T42	TEST 1693 1724	right supraclavicular LN biopsy
T43	PROBLEM 1726 1751	metastatic adenocarcinoma
T44	PROBLEM 1757 1771	breast primary
T45	TEST 1773 1776	CK7
T46	TEST 1778 1783	GATA3
T47	TEST 1785 1787	ER
T48	TEST 1800 1804	CK20
T49	TEST 1806 1810	TTF1
T50	TEST 1812 1825	thyroglobulin
T51	TEST 1827 1833	napsin
T52	TEST 1835 1846	mammaglobin
T53	TEST 1860 1862	ER
T54	TEST 1872 1874	PR
T55	TEST 1883 1887	HER2
T56	TEST 1899 1902	IHC
T57	TEST 1906 1910	FISH
T58	TEST 1932 1964	bilateral diagnostic 
 mammogram
T59	PROBLEM 1966 1995	extremely dense breast tissue
T60	PROBLEM 2012 2047	primary malignancy in either breast
T61	PROBLEM 2049 2079	right axillary lymphadenopathy
T62	PROBLEM 2090 2114	an enlarged calcified LN
T63	TEST 2116 2139	right breast ultrasound
T64	PROBLEM 2202 2228	enlarged right axillary LN
T65	PROBLEM 2234 2248	calcifications
T66	TEST 2261 2267	PET/CT
T67	PROBLEM 2269 2304	multiple FDG-avid right cervical LN
T68	TEST 2320 2323	SUV
T69	TEST 2332 2345	jugular chain
T70	TEST 2347 2357	left Vb LN
T71	TEST 2367 2370	SUV
T72	PROBLEM 2377 2416	scattered subcentimeter thyroid nodules
T73	PROBLEM 2433 2468	multiple FDG-avid right axillary LN
T74	TEST 2484 2487	SUV
T75	TEST 2494 2518	right supraclavicular LN
T76	TEST 2528 2531	SUV
T77	PROBLEM 2538 2577	heterogeneous breast tissue bilaterally
T78	PROBLEM 2583 2608	heterogeneous FDG-avidity
T79	PROBLEM 2615 2674	slightly nodular area of uptake in upper outer right breast
T80	TEST 2687 2697	MRI breast
T81	PROBLEM 2699 2728	marked background enhancement
T82	PROBLEM 2734 2772	the most confluent area of enhancement
T83	PROBLEM 2882 2930	superficial and smaller right axillary tail mass
T84	PROBLEM 2983 2997	calcifications
T85	TEST 3006 3015	mammogram
T86	PROBLEM 3017 3052	markedly enlarged right axillary LN
T87	PROBLEM 3058 3076	cortical thickness
T88	PROBLEM 3178 3196	a cancer diagnosis
T89	PROBLEM 3317 3341	metastatic breast cancer
T90	PROBLEM 3533 3542	Back pain
T91	PROBLEM 3548 3561	Breast cancer
T92	PROBLEM 3567 3577	Depression
T93	PROBLEM 3583 3595	Hypertension
T94	PROBLEM 3601 3608	Obesity
T95	PROBLEM 3614 3632	Seasonal allergies
T96	PROBLEM 3746 3763	Cerebral aneurysm
T97	PROBLEM 3776 3784	Melanoma
T98	PROBLEM 3797 3817	Basal cell carcinoma
T99	PROBLEM 3830 3853	Squamous cell carcinoma
T100	PROBLEM 3866 3874	Skin ca.
T101	PROBLEM 3895 3901	Cancer
T102	TREATMENT 4641 4666	buPROPion (WELLBUTRIN SR)
T103	TREATMENT 4735 4754	cetirizine (ZYRTEC)
T104	TREATMENT 4828 4852	docusate sodium (COLACE)
T105	PROBLEM 4941 4953	Constipation
T106	TREATMENT 4972 4992	hydrOXYzine (ATARAX)
T107	PROBLEM 5062 5069	Itching
T108	TREATMENT 5077 5101	ibuprofen (ADVIL,MOTRIN)
T109	PROBLEM 5188 5192	Pain
T110	TREATMENT 5210 5214	iron
T111	TREATMENT 5253 5274	labetalol (NORMODYNE)
T112	TREATMENT 5353 5385	FOLIC ACID (PRENATAL MULTI ORAL)
T113	TREATMENT 5407 5430	triamcinolone (KENALOG)
T114	TREATMENT 5529 5563	Fluoxetine      zolpidem (AMBIEN)
T115	PROBLEM 5617 5622	Sleep
T116	TREATMENT 5665 5676	medications
T117	PROBLEM 5713 5728	Known Allergies
T118	PROBLEM 5769 5776	fatigue
T119	PROBLEM 5781 5792	weight loss
T120	Symptom 5805 5819	vision changes
T121	Symptom 5822 5826	HENT
T122	Symptom 5832 5849	change in hearing
T123	Symptom 5856 5871	nasal discharge
T124	Symptom 5875 5891	sinus tenderness
T125	Symptom 5896 5917	difficulty swallowing
T126	Symptom 5922 5933	mouth sores
T127	Symptom 5938 5949	sore throat
T128	Symptom 5964 5975	breast pain
T129	Symptom 5994 5999	cough
T130	Symptom 6004 6011	dyspnea
T131	Symptom 6016 6024	wheezing
T132	Symptom 6047 6057	chest pain
T133	Symptom 6062 6074	palpitations
T134	Symptom 6079 6100	lower extremity edema
T135	Symptom 6111 6120	heartburn
T136	Symptom 6125 6131	nausea
T137	Symptom 6136 6142	emesis
T138	Symptom 6147 6161	abdominal pain
T139	Symptom 6166 6174	diarrhea
T140	Symptom 6179 6191	constipation
T141	Symptom 6196 6202	melena
T142	Symptom 6207 6219	hematochezia
T143	Symptom 6230 6245	suprapubic pain
T144	Symptom 6250 6257	dysuria
T145	Symptom 6262 6278	vaginal bleeding
T146	Symptom 6302 6313	joint aches
T147	Symptom 6318 6333	joint stiffness
T148	Symptom 6338 6349	muscle pain
T149	Symptom 6354 6363	bone pain
T150	PROBLEM 6381 6402	heat/cold intolerance
T151	PROBLEM 6407 6418	hot flashes
T152	PROBLEM 6433 6452	swollen lymph nodes
T153	PROBLEM 6457 6470	easy bruising
T154	PROBLEM 6471 6479	bleeding
T155	PROBLEM 6484 6494	lymphedema
T156	PROBLEM 6515 6524	headaches
T157	PROBLEM 6529 6538	dizziness
T158	PROBLEM 6543 6551	numbness
T159	PROBLEM 6552 6560	tingling
T160	PROBLEM 6565 6570	falls
T161	PROBLEM 6592 6599	anxiety
T162	PROBLEM 6604 6614	depression
T163	PROBLEM 6627 6633	rashes
T164	PROBLEM 6634 6641	lesions
T165	PROBLEM 6646 6657	diaphoresis
T166	TEST 6681 6685	ECOG
T167	TEST 6690 6701	Vital Signs
T168	TEST 6704 6706	BP
T169	TEST 6716 6721	Pulse
T170	TEST 6727 6731	Temp
T171	TEST 6737 6738	C
T172	TEST 6749 6754	Oral)
T173	TEST 6758 6762	Resp
T174	TEST 6768 6770	Ht
T175	TEST 6793 6795	Wt
T176	TEST 6822 6825	LMP
T177	TEST 6852 6856	SpO2
T178	TEST 6863 6866	BMI
T179	PROBLEM 6904 6907	NAD
T180	PROBLEM 6923 6932	anicteric
T181	PROBLEM 6962 6971	nontender
T182	PROBLEM 7010 7018	erythema
T183	PROBLEM 7020 7030	stomatitis
T184	PROBLEM 7035 7055	thrush   Lymph Nodes
T185	TEST 7086 7096	percussion
T186	TEST 7109 7112	CTA
T187	PROBLEM 7129 7136	wheezes
T188	PROBLEM 7138 7145	rhonchi
T189	PROBLEM 7150 7158	crackles
T190	PROBLEM 7214 7221	murmurs
T191	PROBLEM 7226 7231	edema
T192	PROBLEM 7245 7263	masses bilaterally
T193	PROBLEM 7300 7310	tenderness
T194	PROBLEM 7315 7325	distention
T195	PROBLEM 7330 7333	HSM
T196	PROBLEM 7356 7387	tenderness over bones or joints
T197	PROBLEM 7508 7510	HI
T198	PROBLEM 7512 7514	SI
T199	PROBLEM 7516 7530	hallucinations
T200	PROBLEM 7532 7540	paranoia
T201	PROBLEM 7545 7554	delusions
T202	PROBLEM 7576 7582	rashes
T203	PROBLEM 7586 7593	lesions
T204	TEST 7610 7624	Available labs
T205	TEST 7626 7635	pathology
T206	TEST 7641 7648	imaging
T207	PROBLEM 8079 8111	Right supraclavicular lymph node
T208	TEST 8113 8145	US guided fine needle aspiration
T209	PROBLEM 8177 8209	Right supraclavicular lymph node
T210	TEST 8211 8243	US guided fine needle aspiration
T211	PROBLEM 8247 8273	Metastatic adenoccarcinoma
T212	PROBLEM 8291 8305	breast primary
T213	TEST 8338 8351	The aspirates
T214	PROBLEM 8356 8375	moderately cellular
T215	PROBLEM 8405 8440	crowded, malignant epithelial cells
T216	PROBLEM 8519 8564	enlarged and angulated  hyperchromatic nuclei
T217	PROBLEM 8570 8603	coarse chromatin, nuclear grooves
T218	PROBLEM 8663 8675	eosinophilic
T219	PROBLEM 8712 8747	A rare intranuclear pseudoinclusion
T220	PROBLEM 8753 8778	scattered mitotic figures
T221	TEST 8839 8865	immunohistochemical stains
T222	TEST 8899 8913	the cell block
T223	TEST 8950 8953	CK7
T224	TEST 8967 8971	CK20
T225	TEST 8985 8998	Thyroglobulin
T226	TEST 9012 9016	TTF1
T227	TEST 9030 9036	Napsin
T228	TEST 9067 9070	p63
T229	TEST 9084 9095	Mammaglobin
T230	TEST 9109 9114	GATA3
T231	TEST 9149 9153	PAX8
T232	PROBLEM 9262 9300	metastatic carcinoma of breast primary
T233	TEST 9319 9352	clinical  and radiologic findings
T234	TEST 9503 9528	Immunohistochemical tests
T235	TEST 9533 9541	estrogen
T236	TEST 9546 9568	progesterone receptors
T237	TEST 9570 9574	HER2
T238	TEST 9580 9583	Ki-
T239	TEST 9604 9622	manual morphometry
T240	TREATMENT 9626 9640	the cell block
T241	TEST 9645 9676	The test for estrogen receptors
T242	TEST 9702 9719	nuclear  staining
T243	PROBLEM 9731 9742	tumor cells
T244	TREATMENT 9744 9771	Internal positive 
 control
T245	TEST 9834 9869	The test for progesterone receptors
T246	PROBLEM 9892 9907	variable  (weak
T247	TEST 9933 9949	nuclear staining
T248	PROBLEM 9960 9971	tumor cells
T249	TREATMENT 9973 9999	Internal  positive control
T250	TEST 10072 10081	HER2 test
T251	PROBLEM 10083 10097	This carcinoma
T252	PROBLEM 10115 10148	HER2 oncoprotein  over-expression
T253	PROBLEM 10176 10190	this carcinoma
T254	TEST 10518 10523	CA125
T255	PROBLEM 10525 10545	Weak patchy staining
T256	TEST 10568 10571	RCC
T257	TEST 10585 10595	Calcitonin
T258	TEST 10609 10650	The additional immunohistochemical stains
T259	TEST 10766 10770	Exam
T260	TEST 10775 10807	Bilateral diagnostic mammography
T261	TEST 10809 10832	right breast ultrasound
T262	TEST 10880 10902	diagnostic mammography
T263	PROBLEM 10919 10944	primary breast malignancy
T264	TEST 10958 10988	recent cervical lymph node FNA
T265	PROBLEM 11002 11023	breast adenocarcinoma
T266	TEST 11025 11034	Receptors
T267	TEST 11086 11104	prior examinations
T268	PROBLEM 11174 11189	extremely dense
T269	TEST 11223 11234	mammography
T270	PROBLEM 11246 11276	right axillary lymphadenopathy
T271	PROBLEM 11287 11319	an enlarged calcified lymph node
T272	PROBLEM 11350 11396	primary malignancy in the right or left breast
T273	PROBLEM 11433 11462	multiple axillary lymph nodes
T274	PROBLEM 11522 11559	an enlarged right axillary lymph node
T275	PROBLEM 11565 11579	calcifications
T276	PROBLEM 11602 11650	the right axillary calcified enlarged lymph node
T277	TEST 11654 11663	mammogram
T278	PROBLEM 11697 11727	Known biopsy proven malignancy
T279	TEST 11729 11736	BI-RADS
T280	TEST 11765 11772	BI-RADS
T281	TEST 11798 11808	Breast MRI
T282	PROBLEM 11825 11861	underlying breast primary malignancy
T283	TEST 11925 11931	PET/CT
T284	PROBLEM 11977 11984	disease
T285	TEST 12048 12056	the exam
T286	TEST 12357 12359	MR
T287	TEST 12437 12457	palpation-guided FNA
T288	PROBLEM 12461 12480	cervical lymph node
T289	PROBLEM 12495 12520	metastatic adenocarcinoma
T290	PROBLEM 12537 12553	breast carcinoma
T291	PROBLEM 12558 12588	definite primary breast lesion
T292	TEST 12603 12612	mammogram
T293	TEST 12617 12627	ultrasound
T294	TEST 12634 12640	PET/CT
T295	PROBLEM 12664 12711	increased FDG avidity in the outer right breast
T296	TEST 12722 12732	evaluation
T297	PROBLEM 12737 12760	a primary breast lesion
T298	TEST 12778 12796	Prior examinations
T299	TEST 12815 12825	ultrasound
T300	TEST 12843 12852	mammogram
T301	TEST 12887 12890	MRI
T302	TEST 12902 12932	This bilateral breast MRI exam
T303	PROBLEM 12946 12975	marked background enhancement
T304	PROBLEM 13006 13041	heterogeneous fibroglandular tissue
T305	PROBLEM 13069 13098	Marked background enhancement
T306	TEST 13225 13252	post-gadolinium axial image
T307	TEST 13259 13273	sagittal image
T308	TEST 13449 13462	recent PET CT
T309	PROBLEM 13465 13520	A more superficial and smaller right axillary tail mass
T310	TEST 13586 13613	post-gadolinium axial image
T311	TEST 13620 13634	sagittal image
T312	PROBLEM 13677 13700	susceptibility artifact
T313	TEST 13704 13714	T1 imaging
T314	PROBLEM 13749 13763	calcifications
T315	TEST 13772 13781	mammogram
T316	PROBLEM 13812 13861	slightly greater intensity than the breast tissue
T317	PROBLEM 13896 13925	Marked background enhancement
T318	PROBLEM 13938 13967	abnormal areas of enhancement
T319	PROBLEM 13993 14003	malignancy
T320	PROBLEM 14031 14075	Markedly enlarged right axillary lymph nodes
T321	TEST 14280 14287	BI-RADS
T322	TEST 14316 14323	BI-RADS
T323	TEST 14362 14384	second look ultrasound
T324	PROBLEM 14422 14480	more confluent enhancement in the upper outer right breast
T325	PROBLEM 14489 14517	the right axillary tail mass
T326	PROBLEM 14542 14559	the calcification
T327	PROBLEM 14571 14577	lesion
T328	TEST 14581 14590	mammogram
T329	TEST 14606 14635	ultrasound-guided core biopsy
T330	TEST 14694 14697	MRI
T331	TEST 14705 14711	biopsy
T332	PROBLEM 14719 14765	Abnormally enlarged right axillary lymph nodes
T333	PROBLEM 14798 14822	known metastatic disease
T334	TEST 14960 14966	PET/CT
T335	TREATMENT 14967 14996	Whole Body (vertex to thighs)
T336	TEST 15068 15075	Staging
T337	PROBLEM 15123 15165	newly diagnosed right supraclavicular node
T338	PROBLEM 15179 15192	breast cancer
T339	PROBLEM 15266 15287	symmetric, FDG uptake
T340	PROBLEM 15370 15381	mass effect
T341	TEST 15389 15401	these images
T342	TEST 15431 15434	MRI
T343	PROBLEM 15462 15503	intracranial and/or skull base metastases
T344	PROBLEM 15538 15588	Multiple hypermetabolic right cervical lymph nodes
T345	TEST 15646 15653	SUV max
T346	PROBLEM 15682 15718	Additional 0.8 cm left Vb lymph node
T347	TEST 15724 15731	SUV max
T348	PROBLEM 15740 15792	Scattered non-FDG avid subcentimeter thyroid nodules
T349	PROBLEM 15805 15855	Multiple hypermetabolic right axillary lymph nodes
T350	TEST 15890 15897	SUV max
T351	PROBLEM 15926 16000	Previously biopsied 0.9 cm hypermetabolic right supraclavicular lymph node
T352	TEST 16006 16013	SUV max
T353	PROBLEM 16022 16049	Heterogeneous breast tissue
T354	PROBLEM 16073 16098	heterogeneous FDG avidity
T355	PROBLEM 16116 16137	increased FDG avidity
T356	PROBLEM 16152 16200	slightly nodular in the upper outer right breast
T357	PROBLEM 16296 16326	hypermetabolic lymphadenopathy
T358	PROBLEM 16351 16369	metastatic disease
T359	PROBLEM 16393 16492	Hypermetabolic ,enlarged ,right supraclavicular, right axillary, and right cervical lymphadenopathy
T360	PROBLEM 16509 16527	metastatic disease
T361	PROBLEM 16535 16582	Mildly hypermetabolic left cervical lymph nodes
T362	PROBLEM 16597 16618	additional metastases
T363	PROBLEM 16660 16687	heterogeneous breast tissue
T364	PROBLEM 16709 16730	increased FDG avidity
T365	TEST 16779 16800	mammographic findings
T366	TEST 16805 16815	This study
T367	PROBLEM 17037 17039	HR
T368	PROBLEM 17041 17054	breast cancer
T369	PROBLEM 17071 17099	a supraclavicular lymph node
T370	PROBLEM 17122 17136	cervical nodes
T371	TREATMENT 17189 17223	complete treatment recommendations
T372	PROBLEM 17304 17343	hormone receptor positive breast cancer
T373	TEST 17386 17393	imaging
T374	TEST 17407 17417	her workup
T375	PROBLEM 17507 17530	a primary breast cancer
T376	PROBLEM 17542 17609	metastasized to axillary, supraclavicular, and cervical lymph nodes
T377	TEST 17661 17674	a core biopsy
T378	PROBLEM 17678 17702	suspicious breast tissue
T379	TEST 17728 17734	an FNA
T380	PROBLEM 17738 17759	a cervical lymph node
T381	PROBLEM 17791 17809	distant metastasis
T382	PROBLEM 17861 17906	a second primary involving her cervical nodes
T383	TEST 17966 17997	breast and cervical LN biopsies
T384	TREATMENT 18038 18051	a de novo MBC
T385	PROBLEM 18103 18106	MBC
T386	PROBLEM 18137 18149	this disease
T387	PROBLEM 18374 18383	a disease
T388	TREATMENT 18488 18497	a therapy
T389	TEST 18561 18565	HER2
T390	TEST 18579 18582	IHC
T391	PROBLEM 18649 18670	HER2 positive disease
T392	TREATMENT 18697 18714	treatment options
T393	TREATMENT 18736 18748	chemotherapy
T394	PROBLEM 18789 18810	HER2 negative disease
T395	TREATMENT 18835 18844	treatment
T396	TREATMENT 18850 18870	antiestrogen therapy
T397	TREATMENT 18876 18888	chemotherapy
T398	TEST 18933 18951	additional testing
T399	TEST 19014 19020	biopsy
T400	PROBLEM 19024 19035	breast mass
T401	PROBLEM 19046 19079	calcified nodule in axillary tail
T402	TEST 19084 19099	cervical LN FNA
T403	TEST 19142 19157	genetic testing
T404	TREATMENT 19296 19314	the treatment plan
T405	TREATMENT 19331 19347	medication risks
T406	TREATMENT 19349 19371	lifestyle modification
T407	TREATMENT 19399 19406	surgery
T408	PROBLEM 19408 19416	symptoms
T409	TREATMENT 19421 19440	therapeutic options
T410	Age 21 23	33
T411	ClinicalCondition 29 42	premenopausal
A2	ChronicVal T411 chronic
A3	ContinuityVal T411 stable
A4	ExperiencerVal T411 patient
T412	BiomarkerName 80 82	HR
A5	HistoryVal T412 new
A6	EpisodeDescription T412 FirstOccurrence
T413	BiomarkerResult 82 83	+
A7	EpisodeDescription T413 FirstOccurrence
A8	BiomarkerResultVal T413 Positive
R1	BiomarkerRel Arg1:T412 Arg2:T413	
T414	Metastasis 84 94	metastatic
A9	HistoryVal T414 new
A10	EpisodeDescription T414 FirstOccurrence
T415	LymphNodeInvolvement 119 130	lymph nodes
A11	ExperiencerVal T415 patient
A12	HistoryVal T415 new
A13	EpisodeDescription T415 FirstOccurrence
T416	Datetime 261 269	10/30/16
T417	ProcedureName 237 246	evaluated
A14	NegationModalityVal T417 affirmed
A15	IntentVal T417 diagnosis
R2	HappensAtOnDuring Arg1:T416 Arg2:T417	
T418	Symptom 322 326	lump
A16	IsPresentOnFirstCancerDiagnosis T418 yes
A17	IsCausedByDiagnosedCancer T418 yes
A18	ChronicVal T418 non-chronic
A19	ContinuityVal T418 new
T419	Site 309 321	lateral neck
T420	Laterality 303 308	right
R3	LateralityOfSite Arg1:T420 Arg2:T419	
R4	SiteOf Arg1:T419 Arg2:T418	
T421	ProcedureName 333 337	exam
A20	IntentVal T421 diagnosis
T422	TestResult 356 373	hard, mobile mass
R5	ResultOfTest Desc:T422 Test:T421	
T423	Size 375 379	1 cm
A21	HistoryVal T423 new
A22	EpisodeDescription T423 FirstOccurrence
R6	TestOrProcedureReveals Test:T421 Desc:T423	
T424	Site 394 406	lateral neck
T425	Laterality 388 393	right
R7	LateralityOfSite Arg1:T425 Arg2:T424	
T426	Duration 442 449	2 weeks
T427	Datetime 484 492	11/09/16
T428	Site 515 526	lymph nodes
T429	Size 552 558	0.5 cm
A24	EpisodeDescription T429 FirstOccurrence
T430	Site 580 594	anterior chain
T431	Laterality 574 579	right
R8	LateralityOfSite Arg1:T431 Arg2:T430	
R9	SiteOf Arg1:T430 Arg2:T429	
T432	Size 596 604	2 x 1 cm
A25	EpisodeDescription T432 FirstOccurrence
T433	Site 644 656	lateral neck
T434	Laterality 638 643	right
R10	LateralityOfSite Arg1:T434 Arg2:T433	
R11	SiteOf Arg1:T433 Arg2:T432	
T435	DiagnosticLabTest 689 692	CBC
T436	Radiology 763 770	imaging
A26	NegationModalityVal T436 hypothetical_in_future
A27	IntentVal T436 diagnosis
T437	Datetime 789 797	12/27/16
T438	Site 829 831	LN
T439	Symptom 849 853	sore
A28	IsPresentOnFirstCancerDiagnosis T439 yes
A29	IsCausedByDiagnosedCancer T439 yes
A30	ChronicVal T439 non-chronic
A31	ContinuityVal T439 worsening
R12	SiteOf Arg1:T438 Arg2:T439	
R13	HappensAtOnDuring Arg1:T437 Arg2:T439	
T440	ProcedureName 875 879	exam
A32	IntentVal T440 diagnosis
T441	Size 923 929	0.5 cm
A33	EpisodeDescription T441 FirstOccurrence
T442	Site 959 977	mid-cervical chain
T443	Laterality 953 958	right
R14	LateralityOfSite Arg1:T443 Arg2:T442	
T444	Datetime 1079 1087	03/26/17
T445	Site 1105 1110	nodes
T446	Symptom 1168 1172	pain
A34	IsPresentOnFirstCancerDiagnosis T446 yes
A35	IsCausedByDiagnosedCancer T446 yes
A36	ChronicVal T446 non-chronic
A37	ContinuityVal T446 worsening
R15	SiteOf Arg1:T445 Arg2:T446	
R16	HappensAtOnDuring Arg1:T444 Arg2:T446	
T447	ProcedureName 1179 1183	exam
A38	IntentVal T447 diagnosis
A39	TreatmentTypeVal T447 others
T448	TestResult 1210 1218	fullness
R17	ResultOfTest Desc:T448 Test:T447	
T449	Site 1249 1285	anterior and superior cervical chain
T450	Laterality 1243 1248	right
R18	LateralityOfSite Arg1:T450 Arg2:T449	
R19	SiteOf Arg1:T449 Arg2:T448	
T451	TestResult 1299 1314	firm round mass
T452	Size 1316 1324	2 x 2 cm
A40	EpisodeDescription T452 FirstOccurrence
T453	Site 1339 1351	lateral neck
T454	Laterality 1333 1338	right
R20	LateralityOfSite Arg1:T454 Arg2:T453	
R21	SiteOf Arg1:T453 Arg2:T451	
R22	ResultOfTest Desc:T451 Test:T447	
T455	Datetime 1399 1407	03/30/17
T456	Radiology 1413 1415	US
A41	IntentVal T456 diagnosis
T457	Site 1408 1412	Neck
R23	SiteOf Arg1:T457 Arg2:T456	
R24	HappensAtOnDuring Arg1:T456 Arg2:T455	
T458	LymphNodeInvolvement 1483 1493	adenopathy
A42	HistoryVal T458 new
A43	EpisodeDescription T458 FirstOccurrence
T459	Site 1435 1482	submandibular, anterior, and posterior cervical
T460	Laterality 1425 1434	bilateral
R25	LateralityOfSite Arg1:T460 Arg2:T459	
R26	SiteOf Arg1:T459 Arg2:T458	
T461	Site 1497 1510	submandibular
T462	Laterality 1495 1496	R
R28	LateralityOfSite Arg1:T462 Arg2:T461	
T463	Size 1511 1523	3.6 x 1.7 cm
A44	EpisodeDescription T463 FirstOccurrence
T464	Site 1527 1550	anterior cervical chain
T465	Laterality 1525 1526	R
R29	LateralityOfSite Arg1:T465 Arg2:T464	
T466	Size 1551 1563	1.0 x 0.8 cm
T467	Site 1567 1584	anterior cervical
T468	Site 1601 1634	posterior lateral neck inferiorly
T469	Site 1650 1657	thyroid
T470	Site 1699 1717	supraclavicular LN
T471	Site 1757 1763	breast
T472	Laterality 1565 1566	L
T473	Laterality 1599 1600	L
T474	Laterality 1693 1698	right
T475	Laterality 1932 1941	bilateral
R27	LateralityOfSite Arg1:T472 Arg2:T467	
R30	LateralityOfSite Arg1:T473 Arg2:T468	
T476	Size 1585 1597	2.7 x 1.0 cm
A45	HistoryVal T476 new
A46	EpisodeDescription T476 FirstOccurrence
T477	Size 1635 1647	0.9 x 0.7 cm
A47	EpisodeDescription T477 FirstOccurrence
T478	Datetime 1674 1682	04/03/17
T479	ProcedureName 1718 1724	biopsy
A48	IntentVal T479 diagnosis
R31	SiteOf Arg1:T470 Arg2:T479	
T480	Histology 1737 1751	adenocarcinoma
A49	HistoryVal T480 new
A50	EpisodeDescription T480 FirstOccurrence
T481	Metastasis 1726 1736	metastatic
A51	EpisodeDescription T481 FirstOccurrence
T482	BiomarkerName 1773 1776	CK7
A52	HistoryVal T482 new
A53	EpisodeDescription T482 FirstOccurrence
T483	BiomarkerName 1778 1783	GATA3
A54	HistoryVal T483 new
A55	EpisodeDescription T483 FirstOccurrence
T484	BiomarkerName 1785 1787	ER
A56	HistoryVal T484 new
A57	EpisodeDescription T484 FirstOccurrence
T485	BiomarkerName 1800 1804	CK20
A58	HistoryVal T485 new
A59	EpisodeDescription T485 FirstOccurrence
T486	BiomarkerName 1806 1810	TTF1
A60	HistoryVal T486 new
A61	EpisodeDescription T486 FirstOccurrence
T487	BiomarkerName 1812 1825	thyroglobulin
A62	HistoryVal T487 new
A63	EpisodeDescription T487 FirstOccurrence
T488	BiomarkerName 1827 1833	napsin
A64	HistoryVal T488 new
A65	EpisodeDescription T488 FirstOccurrence
T489	BiomarkerName 1835 1846	mammaglobin
A66	HistoryVal T489 new
A67	EpisodeDescription T489 FirstOccurrence
T490	BiomarkerName 1860 1862	ER
A68	HistoryVal T490 new
A69	EpisodeDescription T490 FirstOccurrence
T491	BiomarkerName 1872 1874	PR
A70	HistoryVal T491 new
A71	EpisodeDescription T491 FirstOccurrence
T492	BiomarkerName 1883 1887	HER2
A72	HistoryVal T492 new
A73	EpisodeDescription T492 FirstOccurrence
T493	BiomarkerResult 1790 1798	positive
A74	EpisodeDescription T493 FirstOccurrence
A75	BiomarkerResultVal T493 Positive
R32	BiomarkerRel Arg1:T482 Arg2:T493	
R33	BiomarkerRel Arg1:T483 Arg2:T493	
R34	BiomarkerRel Arg1:T484 Arg2:T493	
T494	BiomarkerResult 1849 1857	negative
A76	EpisodeDescription T494 FirstOccurrence
A77	BiomarkerResultVal T494 Negative
R35	BiomarkerRel Arg1:T489 Arg2:T494	
R36	BiomarkerRel Arg1:T488 Arg2:T494	
R37	BiomarkerRel Arg1:T487 Arg2:T494	
R38	BiomarkerRel Arg1:T486 Arg2:T494	
R39	BiomarkerRel Arg1:T485 Arg2:T494	
T495	BiomarkerResult 1862 1870	+ (>90%)
A78	EpisodeDescription T495 FirstOccurrence
A79	BiomarkerResultVal T495 Positive
R40	BiomarkerRel Arg1:T490 Arg2:T495	
T496	BiomarkerResult 1874 1881	+ (50%)
A80	EpisodeDescription T496 FirstOccurrence
A81	BiomarkerResultVal T496 Positive
R41	BiomarkerRel Arg1:T491 Arg2:T496	
T497	BiomarkerResult 1888 1897	equivocal
A82	EpisodeDescription T497 FirstOccurrence
A83	BiomarkerResultVal T497 Unclear
R42	BiomarkerRel Arg1:T492 Arg2:T497	
T498	Pathology 1899 1902	IHC
A84	IntentVal T498 diagnosis
T499	RadPathResult 1903 1904	2
A85	RadPathResultVal T499 InitialCancerDiagnosis
R43	ResultOfTest Desc:T499 Test:T498	
T500	Pathology 1906 1910	FISH
A86	IntentVal T500 diagnosis
T501	Datetime 1923 1931	04/10/17
T502	Radiology 1955 1964	mammogram
A87	IntentVal T502 diagnosis
R44	HappensAtOnDuring Arg1:T501 Arg2:T502	
T503	Site 1982 1988	breast
T504	Site 2041 2047	breast
T505	Site 2055 2063	axillary
T506	Site 2122 2128	breast
T510	Site 2332 2345	jugular chain
T511	Site 2401 2408	thyroid
T514	Site 2552 2558	breast
T515	Site 2668 2674	breast
T516	Site 2650 2661	upper outer
T517	Site 2691 2697	breast
T518	Site 2791 2809	upper outer breast
T519	Site 2912 2925	axillary tail
T520	Site 3041 3052	axillary LN
T521	Laterality 2049 2054	right
T522	Laterality 2116 2121	right
T523	Laterality 2211 2216	right
T524	Laterality 2287 2292	right
T525	Laterality 2347 2351	left
T526	Laterality 2451 2456	right
T527	Laterality 2494 2499	right
T528	Laterality 2662 2667	right
T529	Laterality 2785 2790	right
T532	Laterality 2906 2911	right
T533	Laterality 3035 3040	right
T534	RadPathResult 2012 2030	primary malignancy
A88	RadPathResultVal T534 NoDisease
R45	ResultOfTest Desc:T534 Test:T502	
T535	LymphNodeInvolvement 2064 2079	lymphadenopathy
A89	EpisodeDescription T535 FirstOccurrence
R46	TestOrProcedureReveals Test:T502 Desc:T535	
T536	LymphNodeInvolvement 2093 2114	enlarged calcified LN
A90	EpisodeDescription T536 FirstOccurrence
R47	TestOrProcedureReveals Test:T502 Desc:T536	
T537	Radiology 2129 2139	ultrasound
A91	IntentVal T537 staging
R48	SiteOf Arg1:T506 Arg2:T537	
R49	LateralityOfSite Arg1:T522 Arg2:T506	
R50	LateralityOfSite Arg1:T521 Arg2:T505	
R51	SiteOf Arg1:T505 Arg2:T535	
R52	SiteOf Arg1:T505 Arg2:T536	
T539	LymphNodeInvolvement 2202 2210	enlarged
A92	HistoryVal T539 new
A93	EpisodeDescription T539 FirstOccurrence
T540	Site 2217 2228	axillary LN
R54	LateralityOfSite Arg1:T523 Arg2:T540	
R55	TestOrProcedureReveals Test:T537 Desc:T539	
T541	Datetime 2252 2260	04/11/17
T542	Radiology 2261 2267	PET/CT
A94	IntentVal T542 staging
R56	HappensAtOnDuring Arg1:T541 Arg2:T542	
T509	Site 2293 2304	cervical LN
R57	LateralityOfSite Arg1:T524 Arg2:T509	
T543	RadPathResult 2269 2286	multiple FDG-avid
A95	RadPathResultVal T543 InitialCancerDiagnosis
R58	SiteOf Arg1:T509 Arg2:T543	
R59	ResultOfTest Desc:T543 Test:T542	
T544	Size 2306 2318	2.2 x 1.8 cm
A96	EpisodeDescription T544 FirstOccurrence
T545	RadPathResult 2320 2327	SUV 6.0
A97	RadPathResultVal T545 InitialCancerDiagnosis
R60	TestOrProcedureReveals Test:T542 Desc:T544	
R62	SiteOf Arg1:T510 Arg2:T543	
T546	Site 2352 2357	Vb LN
R63	LateralityOfSite Arg1:T525 Arg2:T546	
T547	Size 2359 2365	0.8 cm
A98	HistoryVal T547 new
A99	EpisodeDescription T547 FirstOccurrence
T548	RadPathResult 2367 2374	SUV 2.4
A100	RadPathResultVal T548 InitialCancerDiagnosis
R64	TestOrProcedureReveals Test:T542 Desc:T547	
R65	NotUndergoneBecauseOf Arg1:T542 Reason:T548	
T512	Site 2457 2468	axillary LN
R66	LateralityOfSite Arg1:T526 Arg2:T512	
T549	RadPathResult 2433 2450	multiple FDG-avid
A101	RadPathResultVal T549 InitialCancerDiagnosis
R67	SiteOf Arg1:T512 Arg2:T549	
R68	ResultOfTest Desc:T549 Test:T542	
T550	RadPathResult 2409 2416	nodules
A102	RadPathResultVal T550 Others
R69	SiteOf Arg1:T511 Arg2:T550	
R70	NotUndergoneBecauseOf Arg1:T542 Reason:T550	
T551	RadPathResult 2418 2430	non-FDG avid
A103	RadPathResultVal T551 Others
R71	SiteOf Arg1:T511 Arg2:T551	
R72	ResultOfTest Desc:T551 Test:T542	
T552	Size 2470 2482	2.7 x 1.7 cm
A104	HistoryVal T552 new
A105	EpisodeDescription T552 FirstOccurrence
T553	RadPathResult 2484 2491	SUV 4.5
A106	RadPathResultVal T553 InitialCancerDiagnosis
R61	ResultOfTest Desc:T545 Test:T542	
R74	ResultOfTest Desc:T553 Test:T542	
T513	Site 2500 2518	supraclavicular LN
R75	LateralityOfSite Arg1:T527 Arg2:T513	
T554	Size 2520 2526	0.9 cm
A107	HistoryVal T554 new
A108	EpisodeDescription T554 FirstOccurrence
T555	Size 2932 2950	1.5 x 0.5 x 1.0 cm
A109	HistoryVal T555 new
A110	EpisodeDescription T555 FirstOccurrence
T556	Size 3084 3088	1 cm
A111	HistoryVal T556 new
A112	EpisodeDescription T556 FirstOccurrence
T557	RadPathResult 2528 2535	SUV 3.5
A113	RadPathResultVal T557 InitialCancerDiagnosis
T558	RadPathResult 2583 2608	heterogeneous FDG-avidity
A114	RadPathResultVal T558 InitialCancerDiagnosis
T559	RadPathResult 3017 3034	markedly enlarged
A115	RadPathResultVal T559 InitialCancerDiagnosis
T560	RadPathResult 2926 2930	mass
A116	RadPathResultVal T560 InitialCancerDiagnosis
T561	RadPathResult 2699 2728	marked background enhancement
A117	RadPathResultVal T561 InitialCancerDiagnosis
T562	RadPathResult 2640 2646	uptake
A118	RadPathResultVal T562 Others
R77	ResultOfTest Desc:T557 Test:T542	
R78	SiteOf Arg1:T514 Arg2:T558	
R79	ResultOfTest Desc:T558 Test:T542	
R80	ResultOfTest Desc:T562 Test:T542	
R81	LateralityOfSite Arg1:T528 Arg2:T516	
R82	LateralityOfSite Arg1:T528 Arg2:T515	
T563	Datetime 2678 2686	04/12/17
T564	Radiology 2687 2690	MRI
A119	IntentVal T564 staging
R83	SiteOf Arg1:T517 Arg2:T564	
R84	HappensAtOnDuring Arg1:T563 Arg2:T564	
R85	ResultOfTest Desc:T561 Test:T564	
R86	LateralityOfSite Arg1:T529 Arg2:T518	
R87	LateralityOfSite Arg1:T532 Arg2:T519	
R88	ResultOfTest Desc:T560 Test:T564	
R90	ResultOfTest Desc:T559 Test:T564	
R91	LateralityOfSite Arg1:T533 Arg2:T520	
R92	SiteOf Arg1:T520 Arg2:T559	
T530	ClinicalCondition 3335 3341	cancer
A120	ChronicVal T530 non-chronic
A121	ContinuityVal T530 new
T531	Metastasis 3317 3327	metastatic
A122	HistoryVal T531 new
A123	EpisodeDescription T531 FirstOccurrence
T565	ClinicalCondition 3366 3374	menarche
A124	ChronicVal T565 non-chronic
A125	ContinuityVal T565 stopped
A126	ExperiencerVal T565 patient
T566	Age 3378 3380	10
R94	BeginsOnOrAt Arg1:T565 Arg2:T566	
T567	TreatmentType 3405 3408	OCP
A128	TreatmentContinuityVal T567 finished
A129	TreatmentTypeVal T567 others
T568	Duration 3413 3420	4 years
T569	ClinicalCondition 3430 3434	G1P1
A131	ContinuityVal T569 stable
T570	Age 3464 3466	31
T571	ClinicalCondition 3447 3456	pregnancy
A133	ChronicVal T571 non-chronic
A134	ContinuityVal T571 stopped
T572	ClinicalCondition 3533 3542	Back pain
A135	ChronicVal T572 chronic
A136	ContinuityVal T572 stable
A137	ExperiencerVal T572 patient
T573	ClinicalCondition 3567 3577	Depression
A138	ChronicVal T573 chronic
A139	ContinuityVal T573 stable
A140	ExperiencerVal T573 patient
T574	ClinicalCondition 3583 3595	Hypertension
A141	ChronicVal T574 chronic
A142	ContinuityVal T574 stable
A143	ExperiencerVal T574 patient
T575	ClinicalCondition 3601 3608	Obesity
A144	ChronicVal T575 chronic
A145	ContinuityVal T575 stable
A146	ExperiencerVal T575 patient
T576	ClinicalCondition 3548 3561	Breast cancer
A147	ChronicVal T576 non-chronic
A148	ContinuityVal T576 new
A149	ExperiencerVal T576 patient
T577	ClinicalCondition 3614 3632	Seasonal allergies
A150	ChronicVal T577 chronic
A151	ContinuityVal T577 stable
T578	ClinicalCondition 3746 3763	Cerebral aneurysm
A152	ExperiencerVal T578 family
T579	ClinicalCondition 3776 3784	Melanoma
A153	ExperiencerVal T579 family
A154	NegationModalityVal T579 negated
T580	ClinicalCondition 3797 3817	Basal cell carcinoma
A155	NegationModalityVal T580 negated
A156	ExperiencerVal T580 family
T581	ClinicalCondition 3830 3853	Squamous cell carcinoma
A157	NegationModalityVal T581 negated
A158	ExperiencerVal T581 family
T582	ClinicalCondition 3866 3873	Skin ca
A159	NegationModalityVal T582 negated
A160	ExperiencerVal T582 family
T583	ClinicalCondition 3895 3901	Cancer
A161	NegationModalityVal T583 negated
A162	ExperiencerVal T583 family
T584	MaritalStatus 3972 3978	Single
A163	IsStoppedOrContinuing T584 continuing
A164	ExperiencerVal T584 patient
T585	Tobacco 4149 4161	Never Smoker
A165	NegationModalityVal T585 negated
T586	Symptom 5769 5776	fatigue
A166	NegationModalityVal T586 negated
T587	Symptom 5781 5792	weight loss
A167	NegationModalityVal T587 negated
A168	NegationModalityVal T120 negated
A169	NegationModalityVal T121 negated
A170	NegationModalityVal T122 negated
A171	NegationModalityVal T123 negated
A172	NegationModalityVal T124 negated
A173	NegationModalityVal T125 negated
A174	NegationModalityVal T126 negated
A175	NegationModalityVal T127 negated
A176	NegationModalityVal T128 negated
A177	NegationModalityVal T129 negated
A178	NegationModalityVal T130 negated
A179	NegationModalityVal T131 negated
A180	NegationModalityVal T132 negated
A181	NegationModalityVal T133 negated
A182	NegationModalityVal T134 negated
A183	NegationModalityVal T135 negated
A184	NegationModalityVal T136 negated
A185	NegationModalityVal T137 negated
A186	NegationModalityVal T138 negated
A187	NegationModalityVal T139 negated
A188	NegationModalityVal T140 negated
A189	NegationModalityVal T141 negated
A190	NegationModalityVal T142 negated
A191	NegationModalityVal T143 negated
A192	NegationModalityVal T144 negated
A193	NegationModalityVal T145 negated
A194	NegationModalityVal T146 negated
A195	NegationModalityVal T147 negated
A196	NegationModalityVal T148 negated
A197	NegationModalityVal T149 negated
T588	Symptom 6381 6402	heat/cold intolerance
A198	NegationModalityVal T588 negated
T589	Symptom 6407 6418	hot flashes
A199	NegationModalityVal T589 negated
T590	Symptom 6457 6479	easy bruising/bleeding
A200	NegationModalityVal T590 negated
T591	Symptom 6484 6494	lymphedema
A201	NegationModalityVal T591 negated
T592	Symptom 6515 6524	headaches
A202	NegationModalityVal T592 negated
T593	Symptom 6529 6538	dizziness
A203	NegationModalityVal T593 negated
T594	Symptom 6543 6560	numbness/tingling
A204	NegationModalityVal T594 negated
T595	Symptom 6565 6570	falls
A205	NegationModalityVal T595 negated
T596	Symptom 6592 6599	anxiety
A206	NegationModalityVal T596 negated
T597	Symptom 6604 6614	depression
A207	NegationModalityVal T597 negated
T598	Symptom 6627 6633	rashes
A208	NegationModalityVal T598 negated
T599	Symptom 6634 6641	lesions
A209	NegationModalityVal T599 negated
T600	Symptom 6646 6657	diaphoresis
A210	NegationModalityVal T600 negated
T601	Symptom 6433 6452	swollen lymph nodes
A211	NegationModalityVal T601 affirmed
A212	IsPresentOnFirstCancerDiagnosis T601 yes
A213	IsCausedByDiagnosedCancer T601 yes
A214	ChronicVal T601 non-chronic
A215	ContinuityVal T601 new
T602	Age 16980 16982	33
T603	ClinicalCondition 16988 17001	premenopausal
A217	ChronicVal T603 chronic
A218	ContinuityVal T603 stable
A219	ExperiencerVal T603 patient
T604	BiomarkerName 17037 17039	HR
A220	HistoryVal T604 new
A221	EpisodeDescription T604 FirstOccurrence
T605	BiomarkerResult 17039 17040	+
A222	BiomarkerResultVal T605 Positive
R95	BiomarkerRel Arg1:T604 Arg2:T605	
T606	ClinicalCondition 17048 17054	cancer
A223	ChronicVal T606 non-chronic
A224	ContinuityVal T606 new
A225	ExperiencerVal T606 patient
T607	Metastasis 17055 17067	metastasized
A226	EpisodeDescription T607 FirstOccurrence
T608	LymphNodeInvolvement 17089 17099	lymph node
A227	HistoryVal T608 new
A228	EpisodeDescription T608 FirstOccurrence
T609	Site 17073 17088	supraclavicular
R96	SiteOf Arg1:T609 Arg2:T608	
T610	Site 17122 17130	cervical
T611	LymphNodeInvolvement 17131 17136	nodes
A229	EpisodeDescription T611 FirstOccurrence
R97	SiteOf Arg1:T610 Arg2:T611	
T612	BiomarkerName 17304 17320	hormone receptor
A230	EpisodeDescription T612 FirstOccurrence
T613	BiomarkerResult 17321 17329	positive
A231	EpisodeDescription T613 FirstOccurrence
A232	BiomarkerResultVal T613 Positive
R98	BiomarkerRel Arg1:T612 Arg2:T613	
T614	ClinicalCondition 17337 17343	cancer
A233	ChronicVal T614 non-chronic
A234	ContinuityVal T614 new
A235	ExperiencerVal T614 patient
T615	ClinicalCondition 17524 17530	cancer
A236	ChronicVal T615 non-chronic
A237	ContinuityVal T615 new
A238	ExperiencerVal T615 patient
T616	Metastasis 17542 17554	metastasized
A239	HistoryVal T616 new
A240	EpisodeDescription T616 FirstOccurrence
T617	Site 17558 17566	axillary
T618	Site 17568 17583	supraclavicular
T619	Site 17589 17597	cervical
T620	LymphNodeInvolvement 17598 17609	lymph nodes
A241	HistoryVal T620 new
A242	EpisodeDescription T620 FirstOccurrence
R99	SiteOf Arg1:T617 Arg2:T616	
R100	SiteOf Arg1:T618 Arg2:T616	
R101	SiteOf Arg1:T619 Arg2:T616	
R102	SiteOf Arg1:T619 Arg2:T620	
R103	SiteOf Arg1:T618 Arg2:T620	
R104	SiteOf Arg1:T617 Arg2:T620	
T621	ProcedureName 17663 17674	core biopsy
A243	NegationModalityVal T621 hypothetical_in_future
A244	IntentVal T621 diagnosis
T622	Site 17689 17695	breast
R105	SiteOf Arg1:T622 Arg2:T621	
T623	ProcedureName 17731 17734	FNA
A245	NegationModalityVal T623 hypothetical_in_future
A246	IntentVal T623 diagnosis
T624	Site 17749 17759	lymph node
R106	SiteOf Arg1:T624 Arg2:T623	
T625	Metastasis 17799 17809	metastasis
A247	NegationModalityVal T625 negated
T626	Site 17892 17906	cervical nodes
T627	ProcedureName 17989 17997	biopsies
A248	NegationModalityVal T627 hypothetical_in_future
A249	IntentVal T627 diagnosis
T628	Site 17977 17988	cervical LN
T629	Site 17966 17972	breast
R107	SiteOf Arg1:T628 Arg2:T627	
R108	SiteOf Arg1:T629 Arg2:T627	
T630	ClinicalCondition 18040 18051	de novo MBC
A250	NegationModalityVal T630 hypothetical_in_future
A251	ChronicVal T630 non-chronic
A252	ContinuityVal T630 new
T631	ClinicalCondition 18103 18106	MBC
A253	NegationModalityVal T631 hypothetical_in_future
A254	ChronicVal T631 non-chronic
A255	ContinuityVal T631 new
T633	BiomarkerName 18561 18565	HER2
A256	EpisodeDescription T633 FirstOccurrence
T634	BiomarkerResult 18566 18575	equivocal
A257	BiomarkerResultVal T634 Unclear
R109	BiomarkerRel Arg1:T633 Arg2:T634	
T635	Pathology 18579 18582	IHC
T636	Pathology 18591 18595	FISH
T637	BiomarkerName 18649 18653	HER2
A258	HistoryVal T637 new
A259	EpisodeDescription T637 FirstOccurrence
T638	BiomarkerName 18789 18793	HER2
A260	HistoryVal T638 new
A261	EpisodeDescription T638 FirstOccurrence
T639	BiomarkerResult 18654 18662	positive
A262	BiomarkerResultVal T639 Positive
T640	BiomarkerResult 18794 18802	negative
A263	BiomarkerResultVal T640 Negative
R111	BiomarkerRel Arg1:T638 Arg2:T640	
A264	NegationModalityVal T637 hypothetical_in_future
A265	NegationModalityVal T638 hypothetical_in_future
R110	BiomarkerRel Arg1:T637 Arg2:T639	
T641	TreatmentType 18736 18748	chemotherapy
A266	NegationModalityVal T641 hypothetical_in_future
A267	TreatmentTypeVal T641 others
A268	TreatmentIntentVal T641 palliative
T642	TreatmentType 18850 18870	antiestrogen therapy
A269	NegationModalityVal T642 hypothetical_in_future
A270	TreatmentIntentVal T642 palliative
T643	TreatmentType 18876 18888	chemotherapy
A271	NegationModalityVal T643 hypothetical_in_future
A272	TreatmentIntentVal T643 palliative
T644	ProcedureName 19004 19020	US-guided biopsy
A273	NegationModalityVal T644 planned_in_future
A274	IntentVal T644 diagnosis
T645	Site 19024 19035	breast mass
T646	Site 19056 19079	nodule in axillary tail
R112	SiteOf Arg1:T645 Arg2:T644	
R113	SiteOf Arg1:T646 Arg2:T644	
T647	ProcedureName 19096 19099	FNA
A275	NegationModalityVal T647 planned_in_future
A276	IntentVal T647 diagnosis
T648	Site 19084 19095	cervical LN
R114	SiteOf Arg1:T648 Arg2:T647	
T649	BiomarkerName 19122 19126	HER2
A277	NegationModalityVal T649 planned_in_future
T650	Pathology 19127 19131	FISH
A278	NegationModalityVal T650 planned_in_future
A279	IntentVal T650 diagnosis
T651	GenomicTest 19142 19157	genetic testing
A280	NegationModalityVal T651 planned_in_future
A281	GenomicTestType T651 Unclear
T652	Symptom 532 550	increasing in size
A282	IsPresentOnFirstCancerDiagnosis T652 yes
A283	IsCausedByDiagnosedCancer T652 yes
R115	SiteOf Arg1:T428 Arg2:T652	
R116	HappensAtOnDuring Arg1:T427 Arg2:T652	
T8	SectionSkip 6664 7723	Physical Exam:   ECOG 0   Vital Signs - BP 134/82 | Pulse 69 | Temp 35.7 C (96.2 F) (Oral)  | Resp 18 | Ht 157.5 cm (5' 2.01") | Wt 80.8 kg (178 lb 3.2 oz) | LMP 09/03/2015 (Exact Date) | SpO2 98% | BMI 32.58 kg/m2   Constitutional - WDWN, NAD  Eyes - sclera anicteric, PERRL, EOMI  HENT - sinuses nontender, nasal mucosa intact, pharynx without erythema, stomatitis, or thrush   Lymph Nodes -   Respiratory - resonant to percussion throughout, CTA bilaterally; no wheezes, rhonchi, or crackles  Cardiovascular - Normal heart rate, normal rhythm, no murmurs, no edema  Breast - no masses bilaterally  GI - Bowel sounds normal, soft; no tenderness, no distention, no HSM  Musculoskeletal - No tenderness over bones or joints.   Neurologic - Alert & oriented x 3, ambulates w/o difficulty, good strength throughout  Psychiatric - Mood stable; no HI, SI, hallucinations, paranoia, or delusions  Skin - warm without rashes or lesions       Studies:  Available labs, pathology, and imaging were reviewed and independently interpreted, as described above in the HPI
A284	SectionSkipType T8 physical_exam
T9	SectionSkip 7728 7808;7811 9761;9764 10738	04/03/17 CYTOPATHOLOGY REPORT  ***** WITH ADDENDUM *****    Patient Name: *****, *****  Med. Rec.#: *****  DOB: 08/20/1983 (Age: 33)  Sex: Female  Accession #: *****-*****  Visit #: *****  Service Date: 04/03/2017  Received: 04/03/2017  Location: *****  Client: *****   Physician(s): ***** *****. ***** ((*****) *****-*****)    Source of Specimen:  Right supraclavicular lymph node, US guided fine needle aspiration    FINAL CYTOLOGIC DIAGNOSIS:  Right supraclavicular lymph node, US guided fine needle aspiration:   Metastatic adenoccarcinoma, consistent with breast primary; see comment.       COMMENTS:   The aspirates are moderately cellular and demonstrate clusters of  crowded, malignant epithelial cells arranged in cohesive aggregates and  papillary-like groups. The cells contain enlarged and angulated  hyperchromatic nuclei with coarse chromatin, nuclear grooves, and one to  multiple nucleoli. The cytoplasm is dense and eosinophilic, imparting  and apocrine appearnce. A rare intranuclear pseudoinclusion and  scattered mitotic figures are identified.    To further evaluate the neoplastic cells immunohistochemical stains were  performed and evaluated on the cell block and show the following  results:  - CK7: Positive  - CK20: Negative  - Thyroglobulin: Negative  - TTF1: Negative  - Napsin: Negative  - p40: Negative  - p63: Negative  - Mammaglobin: Negative  - GATA3: Positive  - GCDFP15: Negative  - PAX8: Negative  - ER: Positive     The cytopathologic and immunohistochemical findings are most compatible  with metastatic carcinoma of breast primary. Correlation with clinical  and radiologic findings is recommended.    ***** *****, NP, at ***** ***** was contacted with the diagnosis on  04/06/2017. She relayed an understanding of the diagnosis.    Immunohistochemical tests for estrogen and progesterone receptors, HER2  and Ki-67 were performed by manual morphometry on the cell block.    The test for estrogen receptors is positive. There is 3+ nuclear  staining in >90% of tumor cells. Internal positive control is present,  and external positive control is appropriate.    The test for progesterone receptors is positive. There is variable  (weak to strong, November 28+) nuclear staining in 50% of tumor cells. Internal  positive control is present, and external positive control is  appropriate.    Result of HER2 test: This carcinoma is equivocal for HER2 oncoprotein  over-expression. The staining intensity of this carcinoma was 2 on a  scale of 0-3.     ***** *****/Pathology Resident   ***** ***** *****/Pathologist  Electronically signed out on *****/*****/***** *****:*****:19    Addendum   Date Ordered:   04/06/2017   Status:  Signed Out    Date Complete:   04/10/2017   By: ***** *****    Date Reported:   04/10/2017     Addendum Diagnosis    - CA125: Weak patchy staining  - CAIX: Negative   - RCC: Negative  - Calcitonin: Negative    The additional immunohistochemical stains support the morphologic  findings. The previously reported diagnosis remains unchanged.
A285	SectionSkipType T9 pathology_report
T10	SectionSkip 10743 11694;11697 13647;13650 15604;15607 16943	Exam Date: 04/10/2017  Exam(s): Bilateral diagnostic mammography, right breast ultrasound    Clinical History:  33-year-old woman having diagnostic mammography to evaluate for primary breast malignancy. Patient had recent cervical lymph node FNA positive for breast adenocarcinoma. Receptors are pending per APEX.    Comparison:  There are no prior examinations available for comparison.    Mammographic Findings:  The breasts are extremely dense, which lowers the sensitivity of mammography.  There is right axillary lymphadenopathy including an enlarged calcified lymph node.  No mammographic features of primary malignancy in the right or left breast.    Ultrasound Findings:  There are multiple axillary lymph nodes with the cortex measuring up to 8mm. Additionally there is an enlarged right axillary lymph node with calcifications, which corresponds to the right axillary calcified enlarged lymph node on mammogram.    IMPRESSION:  Right breast: Known biopsy proven malignancy (BI-RADS 6).  Left breast: Negative (BI-RADS 1).    Recommendations:  Breast MRI to evaluate for underlying breast primary malignancy which is scheduled for 04/12/17. Patient is also scheduled for PET/CT tomorrow to evaluate for additional sites of disease.    Findings and management plan discussed with patient during the exam by Dr. *****.    A letter explaining this interpretation in lay language has been sent to the patient.    Radiologist  ***** *****. *****, M.D., Ph.D.    <This report was electronically signed by ***** *****. *****, M.D., Ph.D. at *****/*****/***** *****:23:13 AM>    Exam Date: 04/12/2017  Exam(s): MR breast bilateral en + un    Clinical History:  33-year-old woman status post palpation-guided FNA of cervical lymph node demonstrating metastatic adenocarcinoma consistent with breast carcinoma, no definite primary breast lesion identified on mammogram and ultrasound, with PET/CT demonstrating possible increased FDG avidity in the outer right breast, here for evaluation for a primary breast lesion.    Comparison:  Prior examinations dated 04/10/2017 (ultrasound) and 04/10/2017 (mammogram) were reviewed for comparison.    MRI Findings:  This bilateral breast MRI exam demonstrates marked background enhancement.  The breasts are composed of heterogeneous fibroglandular tissue and fat.    RIGHT Breast:  Marked background enhancement is seen, with the most confluent area of enhancement occurring in the right upper outer breast, posterior depth (best seen on post-gadolinium axial image #101, sagittal image #363), measuring up to 3.5 cm in AP dimension. This is only slightly more prominent on the right compared with the left side, and appears to correspond with the area noted on recent PET CT.  A more superficial and smaller right axillary tail mass is seen measuring approximately 1.5 x 0.5 x 1.0 cm (best seen on post-gadolinium axial image #104, sagittal image #369), which demonstrates suggestion of susceptibility artifact on T1 imaging and may correspond to the area of calcifications seen on mammogram. This appears to enhance with slightly greater intensity than the breast tissue described above.    LEFT Breast:  Marked background enhancement is seen. No abnormal areas of enhancement or other MRI features of malignancy are identified.    OTHER:  Markedly enlarged right axillary lymph nodes are seen with cortical thickness measuring up to 1 cm. Left axillary lymph nodes are unremarkable. Visualized abdomen and remainder of the chest is unremarkable.    IMPRESSION:  Right breast: Suspicious (BI-RADS 4).  Left breast: Negative (BI-RADS 1).    Recommendations:  1. Recommend second look ultrasound to evaluate 2 areas: (1) the area of more confluent enhancement in the upper outer right breast and (2) the right axillary tail mass which may correspond to the calcification-containing lesion on mammogram, with plan for ultrasound-guided core biopsy of these areas if correlates can be found, else recommend MRI-guided biopsy.    2. Abnormally enlarged right axillary lymph nodes are again seen, compatible with known metastatic disease.    Radiologist  ***** *****, MD    <This report was electronically signed by ***** *****, MD at *****/*****/***** *****:*****:17 PM>    PET/CT Whole Body (vertex to thighs) *****/*****/***** 9:49 AM    COMPARISON: None    REASON FOR THE STUDY: Staging.    CLINICAL HISTORY: 33 years old Female with newly diagnosed right supraclavicular node positive for breast cancer.      FINDINGS:    Brain: Study limited by patient motion. Unremarkable, symmetric, FDG uptake is seen throughout the cortical gray matter, basal ganglia and the cerebellum. No mass effect. While these images appear within normal limits, MRI is recommended to rule out intracranial and/or skull base metastases if clinically indicated.    Neck: Multiple hypermetabolic right cervical lymph nodes measuring up to 2.2 x 1.8 cm in the jugular chain with SUV max of 6.0 (series 3 image 50). Additional 0.8 cm left Vb lymph node with SUV max of 2.4. Scattered non-FDG avid subcentimeter thyroid nodules.     Chest: Multiple hypermetabolic right axillary lymph nodes measuring up to 2.7 x 1.7 cm with SUV max of 4.5 (series 3 image 67). Previously biopsied 0.9 cm hypermetabolic right supraclavicular lymph node with SUV max of 3.5. Heterogeneous breast tissue noted bilaterally with heterogeneous FDG avidity, with an area of increased FDG avidity which appears slightly nodular in the upper outer right breast. Lungs are clear.     Abdomen/Pelvis: Unremarkable abdomino-pelvic organs. Normal appendix. No hypermetabolic lymphadenopathy.    Musculoskeletal: No metastatic disease.    IMPRESSION:     1. Hypermetabolic ,enlarged ,right supraclavicular, right axillary, and right cervical lymphadenopathy compatible with metastatic disease.    2. Mildly hypermetabolic left cervical lymph nodes may represent additional metastases.    3. No definite primary seen, however heterogeneous breast tissue with nodular area of increased FDG avidity noted in the outer right breast. Correlate with mammographic findings.    This study was reviewed by attendings Dr. ***** ***** from ***** ***** and Dr. ***** ***** ***** of Nuclear Medicine.    END OF IMPRESSION
A286	SectionSkipType T10 radiology_report
T11	ClinicalCondition 102 108	cancer
T653	Site 95 101	breast
R117	SiteOf Arg1:T653 Arg2:T11	
R118	TumorDesc TumorDetails:T11 Desc:T414	
R119	TumorDesc TumorDetails:T11 Desc:T412	
R120	TumorDesc TumorDetails:T11 Desc:T415	
R121	SiteOf Arg1:T442 Arg2:T441	
R122	TestOrProcedureReveals Test:T447 Desc:T452	
R123	TestOrProcedureReveals Test:T456 Desc:T458	
R124	TestOrProcedureReveals Test:T456 Desc:T463	
R125	SiteOf Arg1:T461 Arg2:T458	
R126	SiteOf Arg1:T464 Arg2:T458	
R127	TestOrProcedureReveals Test:T456 Desc:T466	
R128	TestOrProcedureReveals Test:T456 Desc:T476	
R129	SiteOf Arg1:T467 Arg2:T476	
R130	SiteOf Arg1:T464 Arg2:T466	
R131	SiteOf Arg1:T461 Arg2:T463	
R132	SiteOf Arg1:T468 Arg2:T477	
R133	TestOrProcedureReveals Test:T456 Desc:T477	
T654	RadPathResult 1658 1670	unremarkable
R134	ResultOfTest Desc:T654 Test:T456	
R135	TestOrProcedureReveals Test:T498 Desc:T492	
R136	TestOrProcedureReveals Test:T479 Desc:T481	
R137	TestOrProcedureReveals Test:T479 Desc:T480	
R138	TestOrProcedureReveals Test:T479 Desc:T482	
R139	TestOrProcedureReveals Test:T479 Desc:T483	
R140	TestOrProcedureReveals Test:T479 Desc:T484	
R141	TestOrProcedureReveals Test:T479 Desc:T485	
R142	TestOrProcedureReveals Test:T479 Desc:T486	
R144	TestOrProcedureReveals Test:T479 Desc:T487	
R143	TestOrProcedureReveals Test:T479 Desc:T488	
R145	TestOrProcedureReveals Test:T479 Desc:T489	
R146	TestOrProcedureReveals Test:T479 Desc:T490	
R147	TestOrProcedureReveals Test:T479 Desc:T491	
R148	TestOrProcedureReveals Test:T479 Desc:T492	
R149	LateralityOfSite Arg1:T475 Arg2:T503	
R150	SiteOf Arg1:T503 Arg2:T502	
R53	SiteOf Arg1:T540 Arg2:T539	
R151	TestOrProcedureReveals Test:T542 Desc:T552	
R152	TestOrProcedureReveals Test:T542 Desc:T554	
T508	Laterality 2566 2577	bilaterally
R153	LateralityOfSite Arg1:T508 Arg2:T514	
R154	TestOrProcedureReveals Test:T542 Desc:T556	
T538	Site 3328 3334	breast
R155	SiteOf Arg1:T538 Arg2:T530	
R156	TestOrProcedureReveals Test:T650 Desc:T649	
R157	TreatmentAdministeredForProblem Treatment:T642 Prob:T638	
R158	NotUndergoneBecauseOf Arg1:T643 Reason:T638	
R159	TreatmentAdministeredForProblem Treatment:T641 Prob:T637	
R160	TestOrProcedureReveals Test:T635 Desc:T633	
A287	NegationModalityVal T636 planned_in_future
T632	Site 17517 17523	breast
R161	SiteOf Arg1:T632 Arg2:T615	
T655	Site 17791 17798	distant
R162	SiteOf Arg1:T655 Arg2:T625	
T656	Site 17330 17336	breast
R163	SiteOf Arg1:T656 Arg2:T614	
R164	TumorDesc TumorDetails:T612 Desc:T614	
T657	Site 17041 17047	breast
R165	SiteOf Arg1:T657 Arg2:T606	
R166	TumorDesc TumorDetails:T604 Desc:T606	
R167	TumorDesc TumorDetails:T607 Desc:T606	
R168	SiteOf Arg1:T609 Arg2:T607	
R169	SiteOf Arg1:T610 Arg2:T607	
T658	SDoH 4498 4504	mother
T659	MaritalStatus 4491 4497	single
T660	ConsumptionQuantity 4213 4224	0.6 oz/week
T661	Drugs 4310 4312	No
A288	NegationModalityVal T661 negated
T662	Alcohol 4284 4295	1 per month
T663	ConsumptionQuantity 4229 4269	1 Standard drinks or equivalent per week
R170	ConsumptionQuantityRel Arg1:T662 Arg2:T663	
R171	ConsumptionQuantityRel Arg1:T662 Arg2:T660	
R172	HappensAtOnDuring Arg1:T571 Arg2:T570	
R173	HappensAtOnDuring Arg1:T567 Arg2:T568	
R174	TumorDesc TumorDetails:T530 Desc:T531	
R176	SiteOf Arg1:T518 Arg2:T561	
R177	SiteOf Arg1:T519 Arg2:T560	
R179	SizeOf Arg1:T423 Arg2:T422	
R180	SizeOf Arg1:T452 Arg2:T451	
T664	LymphNodeInvolvement 515 526	lymph nodes
A289	NegationModalityVal T664 uncertain_in_present
T665	Symptom 559 570	mobile mass
A290	IsPresentOnFirstCancerDiagnosis T665 yes
A291	IsCausedByDiagnosedCancer T665 yes
A292	ContinuityVal T665 new
R181	SizeOf Arg1:T429 Arg2:T665	
T666	Symptom 605 609	mass
A293	IsPresentOnFirstCancerDiagnosis T666 yes
A294	IsCausedByDiagnosedCancer T666 yes
A295	ChronicVal T666 non-chronic
A296	ContinuityVal T666 new
R182	SizeOf Arg1:T432 Arg2:T666	
R183	SizeOf Arg1:T463 Arg2:T458	
R184	SizeOf Arg1:T466 Arg2:T458	
R185	SizeOf Arg1:T476 Arg2:T458	
T667	LymphNodeInvolvement 943 945	LN
A297	NegationModalityVal T667 uncertain_in_present
R186	SizeOf Arg1:T441 Arg2:T667	
R187	HappensAtOnDuring Arg1:T478 Arg2:T479	
R188	SizeOf Arg1:T477 Arg2:T458	
T668	Size 2179 2185	0.8 cm
T669	LymphNodeInvolvement 2159 2161	LN
A298	EpisodeDescription T669 FirstOccurrence
R189	SizeOf Arg1:T668 Arg2:T669	
T670	Site 2150 2158	axillary
R190	SiteOf Arg1:T670 Arg2:T669	
R191	TestOrProcedureReveals Test:T537 Desc:T669	
T507	LymphNodeInvolvement 2302 2304	LN
A299	EpisodeDescription T507 FirstOccurrence
R192	SizeOf Arg1:T544 Arg2:T507	
T671	LymphNodeInvolvement 2355 2357	LN
A300	EpisodeDescription T671 FirstOccurrence
T672	LymphNodeInvolvement 2466 2468	LN
A301	EpisodeDescription T672 FirstOccurrence
T673	LymphNodeInvolvement 2516 2518	LN
A302	EpisodeDescription T673 FirstOccurrence
R193	SizeOf Arg1:T547 Arg2:T671	
R194	SizeOf Arg1:T552 Arg2:T672	
R73	SizeOf Arg1:T554 Arg2:T673	
T674	Size 2774 2780	3.5 cm
A303	EpisodeDescription T674 FirstOccurrence
R76	SizeOf Arg1:T674 Arg2:T561	
R175	ResultOfTest Desc:T560 Test:T564	
T675	LymphNodeInvolvement 3050 3052	LN
A304	EpisodeDescription T675 FirstOccurrence
R93	SizeOf Arg1:T556 Arg2:T675	
T676	hpi_start 0 2	ID
T677	hpi_end 3479 3480	.
T678	ap_start 16947 16957	Assessment
T679	ap_end 19150 19157	testing
R89	SizeOf Arg1:T555 Arg2:T560	
